HIV/HBV合并感染患者接受替诺福韦治疗后的肝细胞癌发病率:筛查策略的相关性
本研究纳入4个欧洲前瞻性队列中3625例HIV/HBV合并感染成人,评估含替诺福韦二吡呋酯(TDF)抗逆转录病毒治疗下肝细胞癌(HCC)发病率及危险因素。随访32673人年,60例(1.7%)发生HCC。TDF使用者中肝硬化者HCC发病率为5.9/1000人年,非肝硬化者为1.17/1000人年;非肝硬化者中仅TDF启动年龄>45岁者发病率超过常用筛查阈值2例/1000人年。
要点
- TDF使用者中,肝硬化者HCC发病率为5.9/1000人年(95%CI 3.60-9.10),非肝硬化者为1.17/1000人年(95%CI 0.56-2.14)。
- TDF启动年龄每增加10年,HCC调整发病率比为2.2(95%CI 1.6-3.0)。
- 非肝硬化者中,仅TDF启动年龄>45岁者HCC发病率超过常用筛查阈值2例/1000人年。
核心结论
- 在HIV/HBV合并感染者中,肝硬化者HCC发病率高,而46岁前启动TDF且无肝硬化者HCC发病率低于筛查阈值。
研究设计与样本
- 多队列研究,纳入4个欧洲前瞻性队列中乙肝表面抗原阳性的HIV感染成人。
- 共纳入3625例HIV/HBV合并感染患者,其中72%已启动含TDF的抗逆转录病毒治疗。
- 主要结局为HCC发生,采用多变量泊松回归评估HCC危险因素。
主要发现
- 随访32673人年期间,60例(1.7%)发生HCC。
- 接受TDF者HCC发病率随时间保持稳定,而未接受TDF者发病率稳步上升。
- 接受TDF者中,肝硬化者HCC发病率为5.9/1000人年(95%CI 3.60-9.10),非肝硬化者为1.17/1000人年(95%CI 0.56-2.14)。
- TDF启动年龄每增加10年,调整发病率比为2.2(95%CI 1.6-3.0);肝硬化者的调整发病率比为4.5(95%CI 2.3-8.9)。
- 非肝硬化者中,仅TDF启动年龄>45岁者HCC发病率超过常用筛查阈值2例/1000人年。
关键数值与推荐
- 常用HCC筛查阈值为2例/1000人年。
- 非肝硬化者中,仅TDF启动年龄>45岁者HCC发病率超过该阈值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Robust data on hepatocellular carcinoma (HCC) incidence among HIV/hepatitis B virus (HBV)-coinfected individuals on antiretroviral therapy (ART) are needed to inform HCC screening strategies. We aimed to evaluate the incidence and risk factors of HCC among HIV/HBV-coinfected individuals on tenofovir disoproxil fumarate (TDF)-containing ART in a large multi-cohort study. METHODS: We included all HIV-infected adults with a positive hepatitis B surface antigen test followed in 4 prospective European cohorts. The primary outcome was the occurrence of HCC. Demographic and clinical information was retrieved from routinely collected data, and liver cirrhosis was defined according to results from liver biopsy or non-invasive measurements. Multivariable Poisson regression was used to assess HCC risk factors. RESULTS: A total of 3,625 HIV/HBV-coinfected patients were included, of whom 72% had started TDF-containing ART. Over 32,673 patient-years (py), 60 individuals (1.7%) developed an HCC. The incidence of HCC remained stable over time among individuals on TDF, whereas it increased steadily among those not on TDF. Among individuals on TDF, the incidence of HCC was 5.9 per 1,000 py (95% CI 3.60-9.10) in cirrhotics and 1.17 per 1,000 py (0.56-2.14) among non-cirrhotics. Age at initiation of TDF (adjusted incidence rate ratio per 10-year increase: 2.2, 95% CI 1.6-3.0) and the presence of liver cirrhosis (4.5, 2.3-8.9) were predictors of HCC. Among non-cirrhotic individuals, the incidence of HCC was only above the commonly used screening threshold of 2 cases per 1,000 py in patients aged >45 years old at TDF initiation. CONCLUSIONS: Whereas the incidence of HCC was high in cirrhotic HIV/HBV-coinfected individuals, it remained below the HCC screening threshold in patients without cirrhosis who started TDF aged <46 years old. LAY SUMMARY: We investigated the incidence of hepatocellular carcinoma in HIV/hepatitis B virus-coinfected individuals from a large multi-cohort study in Europe. Over 32,673 patient-years, 60 individuals (1.7%) developed hepatocellular carcinoma. The incidence of hepatocellular carcinoma remained low in patients without cirrhosis, who started on tenofovir disoproxil fumarate when aged <46 years old.
引用
- Wandeler G, Mauron E, Atkinson A, et al. Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies. J Hepatol. 2019. PMID: 30965070. doi:10.1016/j.jhep.2019.03.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。